| Literature DB >> 27701471 |
Gaiyan Wen1,2, Xinchun Liu2, Lihua Huang3, Jingxian Shu1,2, Nana Xu1,2, Ruifang Chen2, Zhijun Huang1,2, Guoping Yang1, Xiaomin Wang1, Yuxia Xiang2, Yao Lu1,2, Hong Yuan1,2.
Abstract
PURPOSE: To explore the readability and content integrity of informed consent forms (ICFs) used in China and to compare the quality of Chinese local ICFs with that of international ICFs.Entities:
Mesh:
Year: 2016 PMID: 27701471 PMCID: PMC5049790 DOI: 10.1371/journal.pone.0164251
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of informed consent forms (N = 155).
| Clinical Trial Parameter | No. Consent Forms | Percentage (%) |
|---|---|---|
| Phase of study | ||
| II | 49 | 31.6 |
| III | 96 | 61.9 |
| IV | 10 | 6.5 |
| Administration Route | ||
| oral | 79 | 51.0 |
| intravenous injection | 39 | 25.2 |
| inhalation | 7 | 4.5 |
| external use | 12 | 7.7 |
| hypodermic injection | 18 | 11.6 |
| Drug Classification | ||
| anti-infective drugs | 27 | 17.4 |
| cardiovascular system drugs | 20 | 12.9 |
| digestive system drugs | 20 | 12.9 |
| endocrine system drugs | 15 | 9.7 |
| analgesic, antipyretic analgesic and anti-gout drugs | 13 | 8.4 |
| antineoplastic drugs | 12 | 7.7 |
| respiratory system drugs | 10 | 6.5 |
| central nervous system drugs | 9 | 5.8 |
| gynecology and reproductive system drugs | 8 | 5.2 |
| others | 21 | 13.5 |
| Sponsor | ||
| Chinese local pharmaceutical companies | 104 | 67.1 |
| International multinational pharmaceutical companies | 51 | 32.9 |
Comparison of the length and readability between Chinese local ICFs and international ICFs.
| ICF information | Total ICFs (N = 155) | Chinese local ICFs (N = 104) | International ICFs (N = 51) | |
|---|---|---|---|---|
| Number of pages | 7(3–25) | 6(3–13) | 14(5–25) | <0.001 |
| Word Count | 5286(1808–21302) | 4383(1807–13049) | 9568(3806–21302) | <0.001 |
| ICF with appropriate section headings, n (%) | 151(97.4) | 101(97.1) | 50(98.0) | 1.000 |
| ICF with flow chart, n (%) | 14(9.0) | 2(1.9) | 12(23.5) | <0.001 |
| Font size of the text, n (%) | <0.001 | |||
| 12 | 92(59.3) | 52(50.0) | 40(78.4) | |
| 10.5 | 57(36.8) | 49(47.1) | 8(15.7) | |
| Other size | 6(3.9) | 3(2.9) | 3(5.9) | |
| Readability score | 4.31(4.02–4.41) | 4.31(4.15–4.41) | 4.36(4.02–4.41) | <0.001 |
Data were presented as the median and range or number and percentage.
Comparison of the distribution between Chinese local ICFs and international ICFs by comprehension score.
| Level | 1 easiest | 2 easy | 3 median | 4 hard | 5 hardest |
|---|---|---|---|---|---|
| Comprehension score | 4.7029–5.0000 | 4.3202–4.7028 | 3.9827–4.3201 | 3.6002–3.9828 | 0.0000–3.6001 |
| Total ICFs | 0 | 99(63.9) | 56(36.1) | 0 | 0 |
| Chinese local ICFs (No.%) | 0 | 55(52.9) | 49(47.1) | 0 | 0 |
| International ICFs (No.%) | 0 | 44(86.3) | 7(13.7) | 0 | 0 |
Comparison of the content between Chinese local ICFs and international ICFs.
| ICF elements, n (%) | Total ICFs (N = 155) | Chinese local ICFs (N = 104) | International ICFs (N = 51) | |
|---|---|---|---|---|
| a statement that this is research | 116(74.8) | 77(74.0) | 39(76.5) | 0.743 |
| an explanation of informed consent | 64(41.3) | 35(33.7) | 29(56.9) | 0.006 |
| confidentiality of records | 153(98.7) | 102(98.1) | 51(100.0) | 1.000 |
| who can access the data | 146(94.2) | 95(91.3) | 51(100.0) | 0.031 |
| follow-up processing of the data/sample | 52(33.5) | 23(22.1) | 29(56.9) | <0.001 |
| research contact person(s) | 152(98.1) | 101(97.1) | 51(100.0) | 0.551 |
| ethics committee contact information | 80(51.6) | 48(46.2) | 32(62.7) | 0.052 |
| right to refuse | 155(100.0) | 104(100.0) | 51(100.0) | 1.000 |
| right to withdraw | 114(73.5) | 74(71.2) | 40(78.4) | 0.334 |
| replacement therapy | 112(72.3) | 69(66.3) | 43(84.3) | 0.019 |
| right to receive new relevant information | 112(72.3) | 65(62.5) | 47(92.2) | <0.001 |
| purpose of the study | 153(98.7) | 102(98.1) | 51(100.0) | 1.000 |
| inclusion/exclusion criteria | 35(22.6) | 28(26.9) | 7(13.7) | 0.065 |
| number of subjects required | 148(95.5) | 97(93.3) | 51(100.0) | 0.096 |
| trial treatment | 123(79.4) | 74(71.2) | 49(96.1) | <0.001 |
| trial procedures | 123(79.4) | 79(76.0) | 44(86.3) | 0.136 |
| duration of the subject’s participation | 138(89.0) | 87(83.7) | 51(100.0) | 0.002 |
| an explanation of the compared, control or placebo group | 111(71.6) | 67(64.4) | 44(86.3) | 0.005 |
| randomized allocation | 136(87.7) | 92(88.5) | 44(86.3) | 0.696 |
| double blinding | 36(23.2) | 14(13.5) | 22(43.1) | <0.001 |
| pregnancy test for female subjects | 116(74.8) | 75(72.1) | 41(80.4) | 0.265 |
| contraception statement | 122(78.7) | 79(76.0) | 43(84.3) | 0.233 |
| foreseeable risks | 143(92.3) | 94(90.4) | 49(96.1) | 0.339 |
| unpredictable risks | 71(45.8) | 36(34.6) | 35(68.6) | <0.001 |
| individual benefit | 147(94.8) | 101(97.1) | 46(90.2) | 0.116 |
| social benefit | 81(52.3) | 39(37.5) | 42(82.4) | <0.001 |
| compensation for injury | 146(94.2) | 95(91.3) | 51(100.0) | 0.031 |
Comparison of the description of alternatives to participation between Chinese local ICFs and international ICFs.
| ICF information | Total ICFs(N = 155) | Chinese local ICFs (N = 104) | International ICFs (N = 51) |
|---|---|---|---|
| Average score | 1.06 | 0.85 | 1.51 |
| Score, n (%) | |||
| 0 | 43(27.7) | 35(33.7) | 8(15.7) |
| 1 | 68(43.9) | 52(50.0) | 16(31.4) |
| 2 | 35(22.6) | 15(14.4) | 20(39.2) |
| 3 | 9(5.8) | 2(1.9) | 7(13.7) |
*P<0.001, Chinese local ICFs vs. International ICFs.